



Cambridge

June 2018

Welcome to your re-branded Cambridge Experimental Cancer Medicine Centre (CECMC) newsletter, which will bring you updates of our current early phase and translational cancer research

We want to keep you updated!

You may be aware that the law on data protection changed with the introduction of the General Data Protection Regulation (GDPR) on 25th May 2018.

You are currently on our distribution list to receive e-mail updates from the Cambridge ECMC (*previously the Cambridge Cancer Trials Centre Early Phase newsletter*).

We would like to keep in touch with you to provide updates and news from the Cambridge ECMC. If you are happy to continue to receive these e-mails, then no action is required.

However, if you no longer wish to receive these e-mail updates please contact us via [email](#) or click [unsubscribe](#) below.

Thank you

News and Updates

Experimental Cancer Medicine PPI Group



We have set up a **dedicated experimental cancer medicine patient and public involvement (PPI) group**. The aim of the group is to focus specifically on our early phase and translational research, bringing the patient voice to the early stages of the research being conducted in Cambridge. The first meeting of the group was held on Tuesday 12 June, where members were brought together for the first time to meet each other and be provided with a general introduction to early phase and translational research being carried out in Cambridge.

It is important to us that the group be representative of the East Anglia region, and so we're keen to hear

about ways that we can target patients and/or members of the public from your hospitals.

If anybody has an interest in hearing more about the group or has suggestions for ways we can target patients and/or members of the public in your areas, please contact [Emma](#), who would be happy to arrange phone calls or visits to your hospital if that would be useful.

Publication

Cook et al. A phase I trial of the γ -secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. *Br J Cancer*, 2018. 118(6):793-801.

Pathway inhibition by γ -secretase inhibitors has been shown to be effective in pre-clinical models of pancreatic cancer, in combination with gemcitabine. In the paper by Cook et al (2018), it was demonstrated that the recommended phase 2 dose (RP2D) of MK-0752 and gemcitabine as single agents could be combined safely.

The full paper can be accessed online [here](#).

CamBMT1 is presented at ECMC Annual Network Meeting



Dr Richard Baird was delighted to present results from phase Ib of the Cambridge Brain Mets Trial 1 (CamBMT1) at the ECMC Annual Network Meeting, held in London on 9th May.

CamBMT1 is a Cambridge-led, investigator initiated trial for patients with operable brain metastases, funded by Cancer Research UK and Boehringer-Ingelheim. CamBMT1 is testing how well the anticancer drug afatinib penetrates into brain metastases, and whether drug delivery might be improved by targeted, low-dose radiotherapy. Phase Ib results were originally presented as an oral abstract at ASCO 2017 (the abstract can be viewed [here](#)). The preliminary PK results are encouraging, with high concentrations of afatinib presented in resected brain mets compared with levels in the bloodstream. Phase II of CamBMT1 is currently underway at multiple ECMCs across the UK and will directly test whether radiotherapy treatment leads to improved drug delivery.

CAM-PLEX is now recruiting patients with pancreatic cancer

The CAM-PLEX study, evaluating AMD3100 (plerixafor) as an immune modulator, has completed its dose escalation phase, and is **now recruiting patients with pancreatic cancer**. Preliminary data from the study was presented by Prof Doug Fearon at the American Association for Cancer Research (AACR) meeting in April 2018. A video of Prof Fearon, outlining the scientific background for the study and the emerging data from this interesting study can be seen [here](#).

The study in Cambridge is led by Dr Bristi Basu and Prof Duncan Jodrell, please contact them for more information. Alternatively, referrals should be sent to Charlotte Scott via [email](#) or call 01223 596105.

Early Phase Trials Team roadshows are available

The Cambridge Early Phase Trials team are keen to get on the road and meet with our referring centres! We can offer bespoke visits for us to come and meet with your team, provide an update on the trials we're currently running (or have coming soon), and give an overview of the work being undertaken here in Cambridge.

If you would be potentially interested in learning more or arranging a visit, please contact Debra Blackstone on 01223 348082.

Cambridge Early Phase Trials

Please see below table for a list of currently recruiting and upcoming trials being conducted at Cambridge by the Early Phase Trials Team (EPCTT).

For information regarding trial referrals, please contact Charlotte Scott via [email](#) or call on 01223 596105

Cambridge Early Phase Trials			
Trial Short Name	Molecular Target (s)	Patient Population	Lead Investigator (s) in Cambridge
Trials opening soon			
AZD1390	ATM with RT	Glioblastoma	S Jeffries/R Baird
Vaper	hTERT	Advanced solid tumours	R.Baird
CALIBRATION	PD-L1	Oesophageal cancer	S Pacey
Trials recruiting currently			
AZD8186	PIK3CB	Prostate, TNBC, NSCLC, with pre-screening for PTEN deficiency	R Baird
Pisarro Study B	P53	Platinum resistant HGSOE (suitable for Caelyx)	B. Basu
Patriot	ATR	Any tumour type – palliative radiotherapy combined with ATR inhibitor	R Baird
PARADIGM 2	PARP	Glioblastoma stratified by MGMT status	S Jefferies/R Baird
CamBMT1	EGFR/HER2	Operable brain metastasis (breast/lung)	R Baird
MP0274	HER2	HER2-positive cancers	R Baird
POSEIDON 2	PI3K	HR+ metastatic breast cancer	R Baird
G1T38	CDK4/6	ER-positive breast cancer, CDK4/6 inhibitor plus fulvestrant	R Baird
IMCgp100 201	Gp100 immunotoxin	Advanced melanoma (HLA-A2+)	C Parkinson/B Basu
OUTREACH MNA-3521	CEBP α	Hepatocellular carcinoma	B Basu
ONX-0801	α -folate receptor	Platinum resistant ovarian cancer	B Basu
BOS172722	Monopolar spindle 1 kinase inhibitor	Solid tumours suitable for weekly taxol	B Basu
MOv18 IgE	IgE antibody/ α -FR	α -Folate receptor over-expressing gynaecological tumours	B Basu
CAMPLEX	CXCR4	Metastatic pancreatic cancer with biopsiable disease	D Jodrell/B Basu
AZD6738 combo with olaparib	ATR/PARP	Gastric cancer (low ATM expression) & BRCA mutation/HRD high breast cancer	D Jodrell
CURIS	PD-1/PD-L1/VISTA	Any tumour site with FDA approved immunotherapy option	S Pacey
STARTRK2	NTRK1/2/3/ROS1/ALK	Proven NTRK1/2/3, ROS1 or ALK gene rearrangements	S Pacey
CALIBRATE	cfDNA evaluation	Patients on early phase clinical trials	R Baird/S Pacey
IBET	Bromodomain	Haematologic malignancies	B Huntly

Working in collaboration with



CANCER
RESEARCH
UK

CAMBRIDGE
CENTRE



For more news and events from the Cancer Research UK Cambridge Centre, visit our [website](#) or [Twitter page](#)



Want to change how you receive these emails?

You can [update your preferences](#) or [unsubscribe from this list](#).

This email was sent to <<Email Address>>

[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)

Cambridge ECMC · Cambridge Cancer Trials Centre, Box 279 (S4) · Addenbrooke's Hospital, Cambridge Biomedical Campus, Hills Road · Cambridge, CB2 0QQ · United Kingdom

MailChimp